US/UK/Canada

Share

Contacts

  • IR contact
    Rydbergs torg 4 SE-224 84 Lund, Sweden
    https://www.camurus.com

    • Links

    Pick a time period -
    Tags ( Active)

    Camurus’ NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA

    PDUFA target action date set to 18 December 2026 Lund, Sweden — 17 July 2026 — Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of 18 December 2026. The resubmission follows the Complete Response Letter (CRL) issued by the FDA on 10 June 2026, which related to observations from a cGMP

    Camurus’ Interim Report Second Quarter 2026

    “Record product sales and strong operating performance” Summary second quarter 2026 April – June · Total revenues increased 4% (3% at CER[1]) to MSEK 702 (676), (32% increase quarter-on-quarter) · Product sales increased 13% (11% at CER[1]) to MSEK 528 (470), (24% increase quarter-on-quarter) · Brixadi[®] royalty revenue increased 42% (37% at CER[1]) to MSEK 127 (89) · Milestone payments MSEK 46 (115) · Operating result MSEK 293 (292) · Cash position at the end of the period BNSEK 4.1 (3.3) · Complete Response Letter received from the FDA for CAM2029 NDA for

    Change in number of shares and votes in Camurus

    Lund — 30 June 2026 — To ensure that the company can fulfill its commitments under the long-term incentive program for employees of the Camurus group as resolved by the 2026 Annual General Meeting (Performance Share Plan 2026/2029), Camurus issued 570,000 series C shares to Carnegie Investment Bank AB (publ) in June 2026. All series C shares have been repurchased by Camurus and converted into common shares in accordance with a conversion provision in the articles of association. As a result of the series C share issue with subsequent repurchase and conversion made under Performance Share

    Camurus provides regulatory update on the US NDA for CAM2029 (Oclaiz™) in acromegaly

    Lund, Sweden — 10 June 2026 — Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (Oclaiz™), octreotide extended-release injection, for the treatment of patients with acromegaly. The CRL relates to the observations from the September 2024 cGMP inspection at a third-party manufacturer. FDA has indicated that satisfactory resolution of these observations, which could include a reinspection of the facility, is required before the NDA can be approved. FDA

    Camurus announces expansion of Lilly collaboration

    Lund, Sweden — 1 June 2026 — Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company (“Lilly”) has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly’s exclusive, global rights to Camurus’ FluidCrystal[®] technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class. The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual GLP-1 and GIP receptor agonists, triple

    Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2026/2029

    Lund, Sweden — 28 May 2026 — The Annual General Meeting of Camurus on 28 May 2026, resolved – for the purpose of ensuring that the company can fulfill its commitments under the long-term incentive program for employees of the Camurus group resolved by the Annual General Meeting (Performance Share Plan 2026/2029) – on a directed share issue of no more than 570,000 redeemable and convertible series C shares. DNB Carnegie Investment Bank AB has subscribed for all 570,000 series C shares. The subscription price amounted to SEK 0.025 per share, which corresponds to the quota value of the shares.

    Resolutions at the annual general meeting 2026 in Camurus

    Lund, Sweden — 28 May 2026 — Camurus AB’s (CAMX) annual general meeting 2026 was held today, Thursday 28 May, at The Loop in Lund. The annual general meeting adopted the presented income statements and balance sheets as well as the remuneration report prepared by the Board and granted discharge of liability to Board members and the CEO. In addition, the following main resolutions were passed. Election of Board members and auditorPer Olof Wallström, Hege Hellstrøm, Jakob Lindberg, Stefan Persson, Erika Söderberg Johnsson, Fredrik Tiberg, Elisabeth Björk and Robert McQuade were re-

    Camurus to present at Jefferies Global Healthcare Conference

    Lund, Sweden — 21 May 2026 — Camurus (NASDAQ STO: CAMX) will participate in the Jefferies Global Healthcare Conference in New York, 2–4 June, 2026. President and CEO Fredrik Tiberg will present on 3 June at 10.55 pm CET, providing an update on the company’s recent developments. A webcast of the presentation will be available through the following link:https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=iX2ZMLifXKSubp3gHo3gjg For more informationFredrik Joabsson, Chief Business Development OfficerTel. +46 (0)70 776 17 37ir@camurus.com (mir@camurus.com)

    Camurus’ Interim Report January-March 2026

    “Q1 performance on track for full-year guidance” Summary first quarter 2026 January - March · Total revenues decreased 5% (increased 3% at CER[1]) to SEK 533 (558) million · Product sales decreased 12% (6% at CER[1]) to SEK 426 (485) million · Royalties increased 44% (59% at CER[1]) to SEK 106 (74) million · Operating result decreased 30% (15% at CER[1]) to SEK 168 (239) million · Profit before tax decreased 28% (14% at CER[1]) to SEK 184 (254) million · The cash position at the end of the quarter was SEK 3.9 (2.9) billion · FDA accepted the Oclaiz™ NDA for

    Camurus Annual Report for 2025

    Lund, Sweden — 29 April 2026 — Camurus (CAMX) today announces that the Annual Report for 2025 now is available at the company’s website: www.camurus.com, and as an attachment to this press release. The Swedish version of the Annual Report is also available on the website in European Single Electronic Format (ESEF). In 2025, Camurus achieved substantial growth of revenue and profitability, while enhancing patient access to effective treatments, expanding the commercial presence, and progressing a pipeline positioned to drive long-term growth. The Annual Report also includes Camurus’

    Notice of annual general meeting 2026 in Camurus AB (publ)

    The shareholders of Camurus AB (publ), Reg. No 556667-9105, are hereby invited to the Annual General Meeting (“AGM”) on 28 May 2026 at 17.00 CEST at The Loop, Rydbergs torg 4, in Lund, Sweden. Registration for the AGM begins at 16.30 CEST. The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the AGM also by postal voting in accordance with the regulations in Camurus’ Articles of Association. Right to participate and notification A) Participation in the meeting room A person who wishes to attend the meeting room in person or

    Change in number of shares and votes in Camurus

    Lund, Sweden — 31 March 2026 — During March 2026, 54,450 employee stock options in Camurus’ employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares. As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 54,450. Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,934,734 corresponding to 59,934,734 votes. As of 31 March 2026, the total number of shares in Camurus amounts to 59,989,184 corresponding to 59,989,184

    Change in number of shares and votes in Camurus

    Lund, Sweden — 27 February 2026 — During February 2026, 54,550 employee stock options in Camurus’ employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares. As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 54,550. Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,880,184 corresponding to 59,880,184 votes. As of 27 February 2026, the total number of shares in Camurus amounts to 59,934,734 corresponding to

    Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer

    Lund, Sweden — 17 February 2026 — Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed as Camurus’ Chief Corporate Development Officer (CCDO) and member of the executive management team, effective 23 March, 2026. Jane brings more than 20 years of experience from senior positions at Novo Nordisk and AstraZeneca within Business and Corporate Development, with a strong track record of driving strategic licensing and M&A transactions, integration processes and alliance management. Most recently, she had the position as Corporate VP in Global Business

    Camurus’ Full Year Report 2025

    “Fourth quarter performance paves the way for a productive 2026” Fourth quarter and full year summary October - December · Total revenues decreased 16% (3% at CER[1]) to SEK 464 (553) million, impacted by a one-time repurchase of inventory of 93 MSEK due to a change of the UK distribution model at the end of the period · Product sales decreased 27% (17% at CER[1]) to SEK 342 (469) million · Royalties increased 47% (82% at CER[1]) to SEK 122 (83) million · Profit before tax decreased 32% (0% at CER[1]) to SEK 127 (186) million · The cash position at the end of the

    Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly

    PDUFA target action date set to 10 June 2026 Lund, Sweden — 9 January 2026 — Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of 10 June 2026. “We look forward to the continued collaboration with the FDA to make Oclaiz available to patients with acromegaly in the US as

    Change in number of shares and votes in Camurus

    Lund, Sweden — 30 December 2025 — During December 2025, 7,350 employee stock options in Camurus’ employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares.  As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 7,350.  Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,872,834 corresponding to 59,872,834 votes. As of 30 December 2025, the total number of shares in Camurus amounts to 59,880,184 corresponding to

    Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism

    Lund, Sweden and Hørsholm, Denmark — 16 December 2025 — Camurus (NASDAQ STO: CAMX) and Gubra, a company specialized in peptide-based drug discovery, today announced that the companies have entered into an exclusive collaboration and license agreement aimed at creating a long-acting therapeutic option for the treatment of hypoparathyroidism. This research and development collaboration will combine Gubra’s parathyroid hormone (PTH) analogue, developed using the company’s proprietary streaMLine peptide discovery platform, with Camurus’ FluidCrystal[®] drug delivery technology to enable

    Change in number of shares and votes in Camurus

    Lund, Sweden — 28 November 2025 — During November 2025, 24,200 employee stock options in Camurus’ employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares. As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 24,200. Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,848,634 corresponding to 59,848,634 votes. As of 28 November 2025, the total number of shares in Camurus amounts to 59,872,834 corresponding to

    Camurus’ Nomination Committee appointed for the Annual General Meeting 2026

    Lund, Sweden — 13 November 2025 — Camurus today announced that the Nomination Committee for the Annual General Meeting (AGM), 2026 consists of the following persons, who together represent about 40 percent of the total number of shares and votes in Camurus based on the last known shareholder information: · Per Sandberg, appointed by Sandberg Development AB, · Arne Lööw, appointed by Fjärde AP-fonden, · Oscar Bergman, appointed by Swedbank Robur Fonder, and · Per Olof Wallström, Chairman of the Board of Camurus The Nomination Committee’s proposals will be presented in the

    Camurus to present at Jefferies London Healthcare Conference

    Lund, Sweden — 12 November 2025 — Camurus (NASDAQ STO: CAMX) will attend the Jefferies Global Healthcare Conference in London 17–20 November. President and CEO Fredrik Tiberg will present on 18 November at 9.30 am CET, giving an update on the company’s recent developments. A webcast of the presentation can be accessed via: https://wsw.com/webcast/jeff332/register.aspx?conf=jeff332&page=camx&url=https://wsw.com/webcast/jeff332/camx/1839403 For more informationFredrik Joabsson, Chief Business Development OfficerTel. +46 (0)70 776 17 37ir@camurus.com (mir@camurus.com) About

    Camurus reports positive topline results for CAM2056, semaglutide monthly depot

    · CAM2056 showed weight and A1c reductions comparable to or exceeding those seen for weekly semaglutide (Wegovy[®]) · Results include a 9.3% weight reduction with CAM2056 vs. 5.2% with weekly semaglutide at Day 85 · Safety and tolerability were consistent with weekly semaglutide · CAM2056 has potential for monthly dosing with rapid initiation Lund, Sweden — 10 November 2025 — Camurus (NASDAQ STO: CAMX) today announced positive topline results from a randomized, active-controlled Phase 1b study evaluating CAM2056, the company’s monthly FluidCrystal[®] semaglutide formulation, in

    Camurus’ Interim Report Third Quarter 2025

    “High profitability and launch preparations for Oczyesa[®]” Summary third quarter 2025 July - September · Total revenues grew 18% (25% at CER[1]) to SEK 567 (480) million · Sales of Buvidal[®] increased 8% (15% at CER[1]) to SEK 455 (421) million · Brixadi[®] royalties increased 91% (100% at CER[1]) to SEK 111 (58) million · Profit before tax increased 48% to SEK 245 (165) million · The cash position at the end of the quarter was SEK 3.5 (2.8) billion · Oczyesa[®] (CAM2029) approved in the UK for the treatment of acromegaly · FDA and the European Commission

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media